A wonderful spring is on its way to the Granite State. The igloo has melted, the lake has thawed, and Lisa continues to respond well to her current treatment. She just started the fifth, 28-day cycle of GDC-0032 and the main side effects continue to be weakness and fatigue.
Lisa is not alone in responding well the GDC-0032. Just this week, at the Annual Meeting of the American Association of Cancer Research, very positive results were reported for the GDC-0032, phase 1a, clinical trial*. Lisa is in the phase 1b group and the result of her study group will be reported at a later date.
Have a great spring 2013!
* Here’s a link to an article about the clinical trial results: